Ardaman Shergill to Male
This is a "connection" page, showing publications Ardaman Shergill has written about Male.
Connection Strength
0.405
-
Survival Outcomes in Early Onset Appendiceal Adenocarcinoma (EOAA). Ann Surg Oncol. 2026 Sep; 33(9):8546-8554.
Score: 0.046
-
Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. Ann Surg Oncol. 2026 Apr; 33(4):3453-3461.
Score: 0.045
-
Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precis Oncol. 2024 05; 8:e2300531.
Score: 0.040
-
Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine. Genes (Basel). 2024 04 25; 15(5).
Score: 0.040
-
Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. J Am Coll Surg. 2024 06 01; 238(6):1013-1020.
Score: 0.039
-
Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703). JAMA. 2026 Sep 01; 336(9):746-754.
Score: 0.012
-
Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. J Surg Oncol. 2026 Jun; 133(8):1016-1022.
Score: 0.011
-
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
Score: 0.011
-
PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precis Oncol. 2026 Feb; 10:e2500741.
Score: 0.011
-
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
Score: 0.011
-
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
Score: 0.011
-
Utilizing Patient Input in Rectal Cancer Trial Design. J Natl Cancer Inst. 2025 Jul 01; 117(7):1421-1428.
Score: 0.011
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
Score: 0.010
-
Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy. JCO Precis Oncol. 2024 09; 8:e2400149.
Score: 0.010
-
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer. 2024 Jul 26; 24(1):901.
Score: 0.010
-
Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 08 20; 42(24):2853-2859.
Score: 0.010
-
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 08 20; 42(24):2918-2927.
Score: 0.010
-
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas. Int J Radiat Oncol Biol Phys. 2024 09 01; 120(1):111-119.
Score: 0.010
-
Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118.
Score: 0.009
-
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. JAMA Oncol. 2023 03 01; 9(3):404-413.
Score: 0.009
-
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022 06; 10(6).
Score: 0.009
-
Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
Score: 0.008
-
DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer. Anticancer Res. 2021 Nov; 41(11):5393-5403.
Score: 0.008
-
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
Score: 0.008
-
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016 Jun; 16(6):350-7.
Score: 0.006